Clinical Trial: A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer

U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07591597) titled 'A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer' on April 13.

Brief Summary: This study aims to evaluate the efficacy and safety of the concurrent combination therapy of S 531011 + fruquintinib or S 531011 + fruquintinib + pembrolizumab in patients with MSS/pMMR colorectal cancer.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Metastatic Colorectal Neoplasms Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer ...